BCAL Diagnostics (BDX) Stock Overview
A screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BDX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BCAL Diagnostics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.10 |
| 52 Week High | AU$0.15 |
| 52 Week Low | AU$0.052 |
| Beta | 0.70 |
| 1 Month Change | -12.50% |
| 3 Month Change | 5.00% |
| 1 Year Change | 7.14% |
| 3 Year Change | 75.00% |
| 5 Year Change | n/a |
| Change since IPO | -57.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| BDX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -12.5% | -4.1% | -2.7% |
| 1Y | 7.1% | -42.7% | 10.2% |
Return vs Industry: BDX exceeded the Australian Biotechs industry which returned -42.7% over the past year.
Return vs Market: BDX underperformed the Australian Market which returned 10.2% over the past year.
Price Volatility
| BDX volatility | |
|---|---|
| BDX Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 4.2% |
Stable Share Price: BDX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: BDX's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Shane Ryan | www.bcaldiagnostics.com |
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx.
BCAL Diagnostics Limited Fundamentals Summary
| BDX fundamental statistics | |
|---|---|
| Market cap | AU$36.87m |
| Earnings (TTM) | -AU$7.16m |
| Revenue (TTM) | AU$2.54m |
Is BDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDX income statement (TTM) | |
|---|---|
| Revenue | AU$2.54m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.54m |
| Other Expenses | AU$9.70m |
| Earnings | -AU$7.16m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 100.00% |
| Net Profit Margin | -282.10% |
| Debt/Equity Ratio | 114.8% |
How did BDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/15 17:38 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BCAL Diagnostics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rosemary Cummins | MST Financial Services Pty Limited |